Pacific Biosciences posted the transcript of its Q2 2026 earnings call, attended by CEO Mark van Oene, CFO Jim Gibson, board member and adviser Christian Henry.
Christian Henry stepped down as president and CEO, effective immediately, remaining on the board and as adviser to van Oene.
Revenue was USD 39 million; guidance cut to USD 155-165 million, citing slower SPRQ-Nx adoption, weak academic funding, slower China recovery.
Sold 20 Revio systems, 26 Vega systems; consumables revenue rose to USD 20.1 million; full-year Revio pull-through seen at USD 200,000-225,000.
Cash flow breakeven target moved to 2028; year-end cash expected at USD 175-185 million; workforce reduction of about 40 employees.
PACB•
